Salvage Radiation Therapy After Radical Prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT Trial.
Peter Meidahl Petersen, Adrian D Cook, Matthew R Sydes...
https://pubmed.ncbi.nlm.nih.gov/37150260/Actively Recruiting
Led by CHU de Quebec-Universite Laval · Updated on 2026-07-01
434
Participants Needed
4
Research Sites
321 weeks
Total Duration
This research compares two different post-operative salvage radiotherapy schedules for men with recurrent prostate cancer after surgery who have detectable PSA levels. The goal is to determine if a shorter treatment plan is as safe and effective as the standard longer schedule. This study is important because cancer can return in many high-risk patients after prostate surgery, and the best radiotherapy approach, including treatment length and pelvic area coverage, remains under study. Participants will receive either the standard radiotherapy with 25 sessions over about 5 weeks delivering 62.5 Gy to the prostate bed and 45 Gy to the pelvis, or a shorter schedule with 20 sessions over about 4 weeks delivering 52.5 Gy to the prostate bed and 43 Gy to the pelvis. Both groups may also receive hormone therapy Androgen Deprivation Therapy for 6 to 24 months, depending on the doctors discretion. Some patients with pelvic nodal disease may receive additional medications for 24 months following a specific protocol. During the study, participants will be monitored for side effects related to urinary and bowel health for up to 24 months after radiotherapy. Researchers will also assess cancer control through PSA levels and disease spread, survival rates, and quality of life using urinary, bowel, and sexual health questionnaires. Follow-up evaluations will continue for up to 10 years, with assessments at regular intervals to understand long-term outcomes and safety. The entire study is expected to last about 12 years, including 2 years for enrollment and 10 years of follow-up.
CONDITIONS
Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.
E
Eric Vigneault, MD, MSc
D
Damien Carignan, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
CHU de Quebec-Universite Laval
Lead Sponsor
TerSera Therapeutics LLC
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 4 to 5 weeks for radiotherapy; 6 to 24 months for hormone therapy
Participants receive either the standard radiotherapy schedule of 25 sessions over about 5 weeks or the shorter schedule of 20 sessions over about 4 weeks. Both treatments target the prostate bed and pelvis using advanced radiotherapy techniques. Some may also receive hormone therapy for 6 to 24 months based on the doctor's recommendation.
Duration - Up to 10 years
Participants are monitored regularly for urinary and bowel side effects, cancer progression, quality of life, and survival for up to 10 years after treatment. Assessments include PSA tests and health questionnaires at scheduled intervals during this period.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Peter Meidahl Petersen, Adrian D Cook, Matthew R Sydes...
https://pubmed.ncbi.nlm.nih.gov/37150260/Alan Pollack, Theodore G Karrison, Alexander G Balogh...
https://pubmed.ncbi.nlm.nih.gov/35569466/Mark K Buyyounouski, Stephanie L Pugh, Ronald C Chen...
https://pubmed.ncbi.nlm.nih.gov/38483412/Chris C Parker, Howard Kynaston, Adrian D Cook...
https://pubmed.ncbi.nlm.nih.gov/38763153/Gerhardt Attard, Laura Murphy, Noel W Clarke...
https://pubmed.ncbi.nlm.nih.gov/34953525/William U Shipley, Wendy Seiferheld, Himanshu R Lukka...
https://pubmed.ncbi.nlm.nih.gov/28146658/CHU de Quebec-Universite Laval
Lead Sponsor
TerSera Therapeutics LLC
Collaborating Sponsor